Subcutaneous CS6253 9-month chronic toxicology GLP study in cynomolgus monkeys to assess safety, tolerability and PK
Active Grant Awarded
- Award ID
- R44AG099463
- Recipient
-
Artery Therapeutics, Inc. UEI JHVKQN55S7Y5
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,267,403
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 11% complete
- Place of performance
- San Ramon, CA 94583, USA
Award details come from USAspending.gov.
About this award
Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Artery Therapeutics, Inc. a grant with $2.267403 million obligated on September 17, 2026, under the Aging Research program (CFDA 93.866). The award funds a 9-month chronic toxicology study of CS6253 in cynomolgus monkeys to assess safety, tolerability, and pharmacokinetics. The study is a GLP-compliant 39-week dosing phase followed by a 4-week recovery phase, conducted under ICH M3 (R2) guidance to industry. CS6253 is Artery's ABCA1 transporter-targeting treatment for hereditary APOE4-associated dementia, including MCI-AD. The source states that animal chronic toxicology studies are required before Phase 2-3 cognition trials in APOE4 carriers with early AD. A prior grant, 1R44AG092185, secured funding for drug substance manufacturing that supports the planned studies pending notice of award. Place of performance is San Ramon, CA 94583, USA, and the ultimate completion date is May 31, 2028.
Description
- Abstract
- Artery therapeutics, INC. (ATI) is developing a highly differentiated, cholesterol-transport-focused treatment for the indication of hereditary APOE4-associated dementia, including MCI-ad, targeting the ABCA1 transporter, i.e., CS6253. In the recently performed phase 1 SAD-MAD study in healthy men and women, CS6253 showed favorable safety-tolerability and pharmacokinetics (PK), prototypical lipid effects with induction of small apoa-I particles and apoe (target engagement proxy) and an amyloid-clearance signal consistent with previous mouse and primate studies. In the phase 1 study, we also performed an exploratory IV-SC bioequivalence sub-study showing that a single CS6253 SC bolus injection of 1 MG/KG was safe (no adverse systemic or local effects). We demonstrated a 77 % bioavailability compared to IV injection further supporting SC route feasibility. With CS6253 showing unequivocal safety, favorable PK including feasibility for SC route of administration, target engagement and an amyloid-clearance signal in human healthy volunteers, IT is timely to prepare for phase 2-3 cognition trials in APOE4 carriers with early ad. The cognition trials typically need 9 months of treatment to detect treatment effects, i.e., separation between the active and placebo arms. Before phase 2-3 studies, animal chronic toxicology studies are required. Under a previous grant (1R44AG092185 - 01A1), ATI has secured funding for manufacturing of drug substance, which supports the planned chronic toxicology studies pending notice of award. ATI now seeks support for the 9-month chronic toxicology cynomolgus monkey study. With this proposal, we will perform a chronic toxicology study following ICH M3 (R2) guidance to industry, performing a GLP-compliant 39-week study followed by a 4-week recovery phase. Methods for test articles (dose formulation analysis and stability testing) and bioanalytical methods for the toxicokinetic part of the study will be GLP compliant. Gross pathology and tissue collection, analysis and storage will follow standard practices. The results will be compiled into a final toxicology report and a toxicokinetic report. Results will furthermore be compilated into electronic common technical document (ECTD) and the standard for exchange of nonclinical data (SEND) format for electronic submission to the FDA. Following completion of the chronic toxicology studies, CS6253 will be ready for cognition assessment in a 9- month randomized controlled phase 2 trial in homozygous APOE4 carriers with ad/adrd.
Quick answers
Who received award R44AG099463?
R44AG099463 was awarded to Artery Therapeutics, Inc. by National Institute on Aging (National Institutes of Health) on September 17, 2026.
How much is award R44AG099463 worth?
$2,267,403 has been obligated on R44AG099463.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award